FibroGen
ISIN US31572Q8087
|WKN A12EZ0
Overview
Description
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 105.19 m |
| EPS, EUR | -2.71 |
| P/B ratio | - |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2023)
| Revenue, EUR | 136.67 m |
| Net income, EUR | -262.91 m |
| Profit margin | -192.37% |
What ETF is FibroGen in?
There are 2 ETFs which contain FibroGen. All of these ETFs are listed in the table below. The ETF with the largest weighting of FibroGen is the CSIF (IE) MSCI USA Small Cap ESG Leaders Blue UCITS ETF B USD.
| ETF | Weight | Investment focus | Holdings | TER | Fund size (in m EUR) | Return 1Y | WKN | ISIN |
|---|---|---|---|---|---|---|---|---|
| CSIF (IE) MSCI USA Small Cap ESG Leaders Blue UCITS ETF B USD | 0.04% | Equity United States Small Cap | 723 | 0.20% | 436 | +18.78% | A2P4U1 | IE00BMDX0L03 |
| SPDR Russell 2000 US Small Cap UCITS ETF | 0.01% | Equity United States Small Cap | 1,795 | 0.30% | 2,573 | +20.81% | A1XFN1 | IE00BJ38QD84 |
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.